-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-504994-19-00
4
2020-06-12
Diffuse Large B-Cell Lymphoma
-
2023-505170-15-00
5
2020-05-15
Adult Subjects With Late Onset Pompe Disease (LOPD)
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-509049-11-00
5
2020-01-01
FIGO stage III ovarian cancer who are eligible for primary cytoreducti
-
2023-506832-33-00
5
2019-11-06
haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
-
2022-502354-14-00
5
2019-10-28
Completely resected Stage IIb/c melanoma
-
2024-510865-41-00
6
2019-09-26
Urothelial cancer
-
2022-502616-37-00
9
2019-07-30
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-509349-11-00
5
2019-03-22
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
-
2023-509119-99-00
4
2019-01-02
Von Hippel-Lindau disease-associated Renal Cell Carcinoma
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2024-517417-32-00
4
2018-11-22
CHRONIC MYELOID LEUKEMIA
-
2023-508551-40-00
6
2018-06-08
Coronary artery multi-vessel disease and left main stenosis
-
2023-506429-13-00
5
2018-05-02
Progressive multiple sclerosis (PMS)
-
2023-505222-34-00
7
2018-04-23
Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-514275-18-00
10
2017-12-06
Mantle Cell Lymphoma (MCL)
-
2023-506399-28-00
5
2017-11-08
Crohn's Disease
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia